Amin Pharmaceutical Co (XTEH:AMIN1) Change In Receivables : IRR0.00 Mil (TTM As of . 20)

View and export this data going back to 1990. Start your Free Trial

What is Amin Pharmaceutical Co Change In Receivables?

Amin Pharmaceutical Co's change in receivables for the quarter that ended in . 20 was IRR0.00 Mil. It means Amin Pharmaceutical Co's Accounts Receivable stayed the same from . 20 to . 20 .

Amin Pharmaceutical Co's change in receivables for the fiscal year that ended in . 20 was IRR0.00 Mil. It means Amin Pharmaceutical Co's Accounts Receivable stayed the same from . 20 to . 20 .

Amin Pharmaceutical Co's Accounts Receivable for the quarter that ended in . 20 was IRR0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Amin Pharmaceutical Co's liquidation value for the six months ended in . 20 was IRR0.00 Mil.

Amin Pharmaceutical Co Change In Receivables Historical Data

The historical data trend for Amin Pharmaceutical Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amin Pharmaceutical Co Change In Receivables Chart

Amin Pharmaceutical Co Annual Data

Trend

Change In Receivables

Amin Pharmaceutical Co Semi-Annual Data

Change In Receivables

Amin Pharmaceutical Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Change In Receivables for the trailing twelve months (TTM) ended in . 20 was IRR0.00 Mil.

Amin Pharmaceutical Co (XTEH:AMIN1) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Amin Pharmaceutical Co's Days Sales Outstanding for the quarter that ended in . 20 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=		/		*	91
=

2. In Ben Graham's calculation of liquidation value, Amin Pharmaceutical Co's accounts receivable are only considered to be worth 75% of book value:

Amin Pharmaceutical Co's liquidation value for the quarter that ended in . 20 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=		-		+	0.75 *	+	0.5 *
=	0.00

Amin Pharmaceutical Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Amin Pharmaceutical Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Amin Pharmaceutical Co (XTEH:AMIN1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amin Pharmaceutical Co (XTEH:AMIN1) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Abolfazl Street, Bostan Heftam West Alley, No. 4, 2nd floor, Marzdaran, Tehran, IRN

Website

https://www.aminpharma.com

Amin Pharmaceutical Co is engaged in the manufacturing of pharmaceutical products, chemical drugs, herbal medicines, and nutritional supplements. It offers antimicrobials, cardiovascular, antidiabetic, cerebellar, gastrointestinal, antibiotic and antifungal, and hypoglycemic agents among others. It develops drugs in the form of plain and overlaid tablets, hard, and soft capsules, oral drops, syrups, and suspensions. Products offered by the company include Acarbose, Sitagliptin, Fampridine, Ofloxacin, Amiodarone, Ibuprofen, Zolpidem, Bilberry, Thyme, and others. Amin also exports its products to Afghanistan, Kazakhstan, Uzbekistan, and Iraq.

Amin Pharmaceutical Co (XTEH:AMIN1) Headlines

No Headlines